Literature DB >> 9486116

Increased natural killer resistance to cyclosporine A by continuous doses of dexamethasone in rats.

E Kamio1, Y Sakamoto, T Kimura, H Takakuwa, M Sakurai, J I Hosokawa, K Nakagawa, F Yoshida, K Tagami.   

Abstract

There is a controversy on the effects of physiological levels of glucocorticoids on natural killer (NK) cytotoxity. Therefore, the effects of exogenously administered dexamethasone on NK cytotoxity in 8-week-old male, Fischer 344 rats were studied. We suppose that the reason for the controversy is insufficient sensitivity of the ordinal radioactive chromium-release assay for normal healthy subjects or animals. Therefore, we developed a new index, a resistance to artificial immunosuppressor, cyclosporine A (CsA) using rat NK activity as an indicator, and named this index, increased resistance to immunosuppressor (IRIS). After some basic, characterizing studies, authors confirmed the fact that continuous doses of dexamethasone (DEX) attenuated NK suppression of CsA. In protocol 4, 18 rats were randomly divided into three groups: the first (DEX + CsA) was injected for 5 days with 0.1 mg DEX/kg/day and a single dose of CsA on the final day, intraperitoneally; the second (SAL + CsA) was treated with an equal volume of saline and CsA; the third (DEX + SAL) was treated with DEX but not CsA. The IRIS in NK activity was increased significantly (P < 0.01) with 5 days injection of DEX. These results demonstrated that physiological, and continuous dosage of glucocorticoids stimulated IRIS in NK activity in rats, and this suggests that appropriate stimuli through the hypothalamic-adrenal axis might be acting, at least, as a defence against immune collapses or dysfunctions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9486116      PMCID: PMC1363804          DOI: 10.1046/j.1365-2567.1997.00363.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  13 in total

1.  Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome.

Authors:  C B Lozzio; B B Lozzio
Journal:  Blood       Date:  1975-03       Impact factor: 22.113

2.  Tissue effects of glucocorticoids.

Authors:  J D Baxter; P H Forsham
Journal:  Am J Med       Date:  1972-11       Impact factor: 4.965

3.  Interleukin-2 augments natural killer cell activity.

Authors:  C S Henney; K Kuribayashi; D E Kern; S Gillis
Journal:  Nature       Date:  1981-05-28       Impact factor: 49.962

4.  Suppression of natural cytotoxicity by spleen cells of hydrocortisone-treated mice.

Authors:  P S Hochman; G Cudkowicz
Journal:  J Immunol       Date:  1979-09       Impact factor: 5.422

Review 5.  Natural killer (NK) cells and their possible roles in resistance against disease.

Authors:  R B Herberman
Journal:  Clin Immunol Rev       Date:  1981

Review 6.  Natural killer cells in relation to disease and treatment.

Authors:  B K Pedersen
Journal:  Allergy       Date:  1985-11       Impact factor: 13.146

7.  Mechanism of action of glucocorticosteroids. Inhibition of T cell proliferation and interleukin 2 production by hydrocortisone is reversed by leukotriene B4.

Authors:  J S Goodwin; D Atluru; S Sierakowski; E A Lianos
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

Review 8.  Glucocorticosteroid therapy: mechanisms of action and clinical considerations.

Authors:  A S Fauci; D C Dale; J E Balow
Journal:  Ann Intern Med       Date:  1976-03       Impact factor: 25.391

Review 9.  The mechanism of action of cyclosporin A and FK506.

Authors:  S L Schreiber; G R Crabtree
Journal:  Immunol Today       Date:  1992-04

10.  Induction of interleukin 2 messenger RNA inhibited by cyclosporin A.

Authors:  J F Elliott; Y Lin; S B Mizel; R C Bleackley; D G Harnish; V Paetkau
Journal:  Science       Date:  1984-12-21       Impact factor: 47.728

View more
  1 in total

1.  Voluntary wheel-running exercise enhances antigen-specific antibody-producing splenic B cell response and prolongs IgG half-life in the blood.

Authors:  Koutarou Suzuki; Kazumi Tagami
Journal:  Eur J Appl Physiol       Date:  2005-06-11       Impact factor: 3.078

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.